Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 1/20 | 0.49 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.49 |
| ▸ | GPR3 | P46089 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | NQO2 | P16083 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MIF | P14174 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2518009 | 1.00 | KCNQ3 (0.49) | KCNQ3KCNQ2GPR3ALDH1A1NPSR1 | |
| SCHEMBL2520354 | 1.00 | KCNQ3 (0.49) | KCNQ3KCNQ2GPR3ALDH1A1NPSR1 | |
| SCHEMBL2518002 | 1.00 | KCNQ3 (0.49) | KCNQ3KCNQ2GPR3ALDH1A1NPSR1 | |
| SCHEMBL5281385 | 0.86 | KCNQ3 (0.46) | KCNQ3KCNQ2GPR3ALDH1A1NPSR1 | |
| SCHEMBL5281384 | 0.86 | KCNQ3 (0.46) | KCNQ3KCNQ2GPR3ALDH1A1NPSR1 | |
| SCHEMBL4615936 | 0.84 | KCNQ3 (0.44) | KCNQ3KCNQ2GPR3ALDH1A1NPSR1 | |
| SCHEMBL4615937 | 0.84 | KCNQ3 (0.44) | KCNQ3KCNQ2GPR3ALDH1A1NPSR1 | |
| SCHEMBL5708494 | 0.76 | KCNQ3 (0.50) | KCNQ3KCNQ2GPR3ALDH1A1NPSR1 | |
| SCHEMBL19449269 | 0.75 | NPC1 (0.56) | KCNQ3KCNQ2ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL170140 | 0.72 | MAPK1 (0.57) | ALDH1A1NPSR1MAPK1TSHRUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2908843-B1 | TREATING CANCER | AGENCY SCIENCE TECH & RES (SG) | 2019-09-04 | — | — | EP | claimed |
| US-9889180-B2 | Method of treating cancer | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-02-13 | — | — | US | claimed |
| US-20150258175-A1 | METHOD OF TREATING CANCER | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-09-17 | — | — | US | claimed |
| EP-2908843-B1 | TREATING CANCER | AGENCY SCIENCE TECH & RES (SG) | 2019-09-04 | — | — | EP | disclosed |
| US-9889180-B2 | Method of treating cancer | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-02-13 | — | — | US | disclosed |
| US-20150258175-A1 | METHOD OF TREATING CANCER | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-09-17 | — | — | US | disclosed |
| WO-2014077784-A1 | METHOD OF TREATING CANCER | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2014-05-22 | — | — | WO | disclosed |
| US-8524682-B2 | Compositions and methods for inhibiting EZH2 | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-09-03 | — | — | US | disclosed |
| US-20110251216-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EZH2 | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-10-13 | — | — | US | disclosed |
| US-20100222420-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EZH2 | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-09-02 | — | — | US | disclosed |
| WO-2009006577-A2 | COMPOSITIONS AND METHODS FOR INHIBITING EZH2 | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-01-08 | — | — | WO | disclosed |
| US-20090012031-A1 | EZH2 Cancer Markers | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251216-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EZH2 | EZH2, BMI1, EZH1 | KCNQ3 4535/4885KCNQ2 4581/4885GPR3 3766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.